Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T5058 |
Pamiparib
BGB-290 |
PARP | Chromatin/Epigenetic; DNA Damage/DNA Repair |
Pamiparib (BGB-290) 是一种具有口服活性、强效、高选择性的 PARP 抑制剂,对PARP1和PARP2的IC50值分别为 0.9 nM 和 0.5 nM。它具有强大的 PARP 捕获能力,具有穿透大脑的能力,可用于研究癌症。 | |||
T28293 |
Pamiparib maleate
BGB290,BGB 290,BGB-29 maleat 0 |
||
Pamiparib is a highly potent and selective PARP inhibitor. BGB-290 selectively binds to PARP and prevents PARP-mediated repair of single-strand DNA breaks via the base-excision repair (BER) pathway. This enhances the accumulation of DNA strand breaks, pro | |||
T71911 |
CGP-11130 HCl
|
||
4-Fluorophenibut (developmental code name CGP-11130; also known as β-(4-fluorophenyl)-γ-aminobutyric acid or β-(4-fluorophenyl)-GABA) is a GABAB receptor agonist which was never marketed. It is selective for the GABAB receptor over the GABAA receptor (IC50 = 1.70 μM and > 100 μM, respectively). The drug is a GABA analogue and is closely related to baclofen (β-(4-chlorophenyl)-GABA), tolibut (β-(4-methylphenyl)-GABA), and phenibut (β-phenyl-GABA). It is less potent as a GABAB receptor agonist t... | |||
T70115 |
Pamiparib hydrate
|
||
Pamiparib, also known as BGB-290, is a highly potent and selective PARP inhibitor with favorable drug metabolism and pharmacokinetic properties. BGB-290 selectively binds to PARP and prevents PARP-mediated repair of single-strand DNA breaks via the base-excision repair (BER) pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability, and eventually leads to apoptosis. BGB-290 may both potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell chemo... |